01:17:08 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Prenumeration

Kalender

2024-11-13 Kvartalsrapport 2024-Q3
2024-10-01 Split LIFE 13:1
2024-08-27 Kvartalsrapport 2024-Q2
2024-05-16 Extra Bolagsstämma 2024
2024-05-08 Kvartalsrapport 2024-Q1
2024-05-02 X-dag ordinarie utdelning LIFE 0.00 NOK
2024-04-30 Årsstämma
2024-02-27 Bokslutskommuniké 2023
2023-11-14 Kvartalsrapport 2023-Q3
2023-08-23 Kvartalsrapport 2023-Q2
2023-05-11 Kvartalsrapport 2023-Q1
2023-05-08 X-dag ordinarie utdelning LIFE 0.00 NOK
2023-04-18 Årsstämma
2023-02-28 Bokslutskommuniké 2022
2022-08-25 Kvartalsrapport 2022-Q2
2022-05-09 X-dag ordinarie utdelning LIFE 0.00 NOK
2022-05-06 Årsstämma
2022-04-21 Bokslutskommuniké 2021
2021-09-30 Extra Bolagsstämma 2021
2021-08-05 Kvartalsrapport 2021-Q2
2021-05-10 X-dag ordinarie utdelning LIFE 0.00 NOK
2021-05-07 Årsstämma
2021-04-20 Bokslutskommuniké 2020
2020-06-26 Årsstämma
2020-06-01 Bokslutskommuniké 2019
2019-02-07 Split LIFE 4:1
2018-12-11 Extra Bolagsstämma 2018

Beskrivning

LandNorge
ListaEuronext Growth Oslo
SektorHälsovård
IndustriMedicinteknik
Lifecare är ett norskt bolag verksamma inom medicinteknik. Idag är bolaget specialiserade inom forskning och utveckling av diabetes. Produkterna är patenterade och används som glukosgivare. Mikrosensorerna injiceras under huden på patientens handled, och fungerar vidare som en realtidsuppdatering av glukosnivån i patienten. Utöver bidrar tekniken med larmsensor samt tillgång till historisk data över patientens glukosnivå. Bolaget etablerades under 2006 och har sitt huvudkontor i Bergen, Norge.
2023-02-06 08:35:12
Ongoing clinical development study confirms Lifecare's expectation of a sensor
longevity that far exceeds the lifetime of existing and commercially available
needle sensors for glucose monitoring.

Today Lifecare can report that sensors used in a three-day clinical study
continue to work in an in vitro set up, showing an operational longevity for a
total of 4 weeks and still ongoing.

The current clinical trial sensor is not the final product, but it already
represents a major step forward for Lifecare's Sencell-technology. - We have 20
people in our outstanding team who have worked intensively to achieve these
results and everyone is thrilled to see the outcome, says CEO Joacim Holter.

Lifecare is developing a Continuous Glucose Monitoring (CGM) sensor at the size
of a grain of rice, with an expected longevity exceeding those of existing
needle based CGM-systems. Lifecares sensor is currently subject to the
first-in-human studies.

Longevity
Lifecare CSO Prof. Andreas Pfützner describes the results as a breakthrough for
the product development of the sensor technology. - Now we have a first proof
that a sensor employing the miniaturized core Sencell technology has been
operational in the human body for several days continues to work in an in vitro
set-up for more than 4 weeks. This is not possible with a commercially available
needle sensor. The in vitro set-up experiment will continue, with the
expectation that we can confirm additional longevity in the months to follow.

Beside the longevity, the study provides already strong indications that our
technology is at least as accurate and may be superior to commercially available
needle sensors. Our study is also an indication of the robustness of the sensing
technology - you can basically take the sensor in and out of the body and it
continues to measure correctly.

- The study shows the stability and robustness of our technology, says Prof.
Pfützner, - and it is an indication that Lifecare is in the process of reaching
the planned long term of longevity.

- As previously communicated, we have prolonged our technology development study
to clear out issues, improve the product, improve the performance of the
product, and improve the longevity of the product, summarizes Joacim Holter.

The current status of the development study firmly confirms the groundbreaking
potential of the Sencell technology.

This is Lifecare
Lifecare is a Bergen-based technology company developing a miniaturized
implantable long-term sensor for correct and continuous monitoring of blood
sugar in people with diabetes. The Company's patented technology also has the
potential for use in various biomarkers. Lifecare AS is listed on Euronext
Growth (LIFE).

Further information
Joacim Holter, CEO, Lifecare AS, joacim.holter@lifecare.no, +47 40 05 90 40

This information is considered to be inside information pursuant to the EU
Market Abuse Regulation and is subject to the disclosure requirements pursuant
to Section 5-12 the Norwegian Securities Trading Act. This stock exchange
announcement was published by Joacim Holter, CEO at Lifecare AS, on 6 February
2023 at 08:35 CET